The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. In this tradition, the focus has been on broad educational outreach, empowering individuals to make informed decisions about their well-being. As this heritage evolves, it naturally extends into more specialized areas where general health principles intersect with specific clinical outcomes. One such area involves the long-term use of certain prescription medications, particularly bisphosphonates like Fosamax, which are commonly prescribed for bone density management. While these therapies have demonstrated efficacy in treating osteoporosis, the scope of health information now requires a nuanced examination of potential adverse effects that may arise from sustained exposure. This pivot from general awareness to targeted risk assessment is critical for individuals who have been prescribed these medications over extended periods. The transition from a broad health context to a focused concern about therapeutic exposure is not a departure from the legacy, but rather a deepening of its application. By maintaining a neutral, evidence-informed perspective, this shift allows for a more precise understanding of how routine medical interventions can, in some cases, lead to unexpected complications.
Fosamax (alendronate) is a bisphosphonate medication prescribed for the treatment of osteoporosis and other bone diseases. A known but rare adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. This section reviews the clinical presentation, pharmacological mechanisms, and risk considerations for patients and attorneys in Virginia. Osteonecrosis of the jaw presents as exposed bone in the oral cavity that persists for more than eight weeks without healing. It is often associated with local factors such as tooth extraction, dental implants, or infection. According to the FDA-approved labeling for Fosamax, ONJ "can occur spontaneously" but is "generally associated with tooth extraction and/or local infection with delayed healing" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition may also involve pain, swelling, and purulent discharge. Diagnosis typically requires clinical examination and imaging, such as panoramic radiographs or CT scans, to assess bone involvement. Multiscale characterization of jawbone tissue has been used to better understand the unique responses of the jaw to bisphosphonate therapy, including the development of ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).
Fosamax belongs to the bisphosphonate class, which inhibits osteoclast-mediated bone resorption. While this mechanism is beneficial for increasing bone density, it can also suppress normal bone turnover, particularly in the jaw. The labeling notes that ONJ has been "reported in patients taking bisphosphonates, including FOSAMAX" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms after starting the drug varies widely, from one day to several months. In clinical studies, the percentage of patients with jaw-related symptoms was similar between Fosamax and placebo groups, indicating that ONJ is a rare event. However, a subset of patients experienced recurrence of symptoms when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
The exact mechanism by which bisphosphonates contribute to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw. They inhibit osteoclast activity and may also affect angiogenesis and immune function. The labeling identifies known risk factors for ONJ, including "invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures)" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These factors suggest that local trauma and infection, combined with suppressed bone remodeling, may precipitate ONJ. Multiscale characterization of jawbone tissue has provided insights into the unique structural and cellular responses that make the jaw susceptible to bisphosphonate-related complications (https://pubmed.ncbi.nlm.nih.gov/40345077/).
The FDA-approved labeling for Fosamax includes a specific warning section (5.4) on osteonecrosis of the jaw. This warning describes the condition, its association with dental procedures, and known risk factors. It also advises that "for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling further states that "discontinue use if severe symptoms develop" and that "most patients had relief of symptoms after stopping" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While these warnings are present, some patients and attorneys may question whether they are sufficiently prominent or detailed to alert prescribers and patients to the risk, especially given the rarity of ONJ. The incidence of ONJ in patients taking bisphosphonates for osteoporosis is considered rare, as noted in a study that found the incidence of ONJ to be "rare" among patients with fragility fractures (https://pubmed.ncbi.nlm.nih.gov/42046648/). However, the potential severity of the condition—requiring surgical intervention and causing significant morbidity—underscores the importance of clear communication. For patients in Virginia who have developed ONJ after taking Fosamax, legal considerations may include whether the manufacturer provided adequate warnings to healthcare providers and patients. Attorneys may examine the labeling to determine if the risks were clearly communicated and if the warnings were updated as new evidence emerged. The labeling does not specify a precise timeline for when ONJ is most likely to occur, but it notes that the time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Attorneys may also consider the role of dental professionals, as a study found that dentists (50.4%) and oral and maxillofacial surgeons (36.8%) were the most common specialists to request consultations regarding bisphosphonates, and that 39.2% of specialists referred ONJ patients to oral and maxillofacial surgery (https://pubmed.ncbi.nlm.nih.gov/40604825/). This suggests that dental providers are often the first to identify potential cases, and their awareness of the drug's risks is critical.
The timeline between starting Fosamax and developing ONJ is variable. The labeling reports that symptoms can appear as early as one day or as late as several months after initiation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is more commonly associated with longer-term use, and the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A study examining bisphosphonate prescription patterns found that interruption of therapy for up to two years after three or five years of use was not associated with an increased risk of fragility fracture, and that ONJ incidence remained rare (https://pubmed.ncbi.nlm.nih.gov/42046648/). This suggests that ONJ is an uncommon outcome even with prolonged use, but when it occurs, it can be a serious complication requiring specialized dental or surgical care.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. A rare but serious side effect is osteonecrosis of the jaw (ONJ), where the jawbone becomes exposed and fails to heal. The FDA labeling notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Symptoms include exposed bone in the mouth that persists for more than eight weeks, pain, swelling, and purulent discharge. It is often associated with dental procedures like tooth extraction or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
The onset of symptoms can range from one day to several months after starting the drug, but it is more common with longer-term use. The risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
The FDA labeling includes a specific warning about ONJ, advising discontinuation before invasive dental procedures. However, some patients and attorneys question whether the warnings are sufficiently prominent given the severity of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.